Ion Exchange: Business Overview & Financial Analysis
Ion Exchange is a leading Indian environment and water management solutions enterprise headquartered in Mumbai, Maharashtra. Promoted by Chairman and Managing Director Rajesh Sharma, the company manufactures ion exchange resins, water treatment plants, membranes, and specialty process chemicals. Operating integrated manufacturing complexes across Ankleshwar, Bharuch, Hosur, Patancheru, and Roha, the enterprise provides total water management solutions across industrial, municipal, institutional, and household segments across 50+ countries globally.
Segment Reorganisation & Revenue Mix of Ion Exchange (Q1 FY2027)
Ion Exchange disaggregated its reporting framework into five primary operational segments during Q1 FY2027 to provide greater business transparency.
- Specialty Chemicals Share – 32.8% of Operating Revenue (Rs 229.70 crore)
- Treatment Solutions Share – 30.0% of Operating Revenue (Rs 209.90 crore)
- Consumer Products Share – 16.0% of Operating Revenue (Rs 112.40 crore)
- Industrial Products Share – 15.0% of Operating Revenue (Rs 105.10 crore)
- Lifecycle Services Share – 10.2% of Operating Revenue (Rs 71.60 crore)
- Total Consolidated Operating Revenue (Q1 FY2027) – Rs 700.50 crore (+20.1% YoY)
Reorganising into five reporting categories highlights that approximately 60% of total turnover stems from high-margin products, chemicals, and recurring services. Specialty chemicals and industrial treatment products serve as core revenue drivers across process industries.
Executable Order Book & Pipeline Scale of Ion Exchange (Q1 FY2027)
The company maintains a strong executable order backlog providing execution visibility across industrial EPC and international engineering projects.
- Total Executable Order Book Backlog – ~Rs 2,473.00 crore (as of June 30, 2026)
- Engineering Projects Order Backlog – ~Rs 2,182.00 crore
- Total Bid Pipeline Scale – ~Rs 9,777.00 crore
- Key International Order Win Value – USD 52.83 million (~Rs 440.00 crore) from Hyundai Engineering & Construction
- UP SWSM Water Supply Project Backlog – ~Rs 281.00 crore
An executable order backlog of ~Rs 2,473.00 crore offers multi-year revenue visibility across engineering execution sites. Securing a USD 52.83 million EPC contract from Hyundai Engineering & Construction strengthens the international project execution footprint.
Manufacturing Scale & Technology Infrastructure of Ion Exchange (FY2026)
Ion Exchange operates global assembly hubs, chemical synthesis plants, and advanced research facilities.
- Total Global Assembly Hubs Base – Assembly units in UAE, Saudi Arabia, South Africa, Indonesia, and Bangladesh
- Primary Manufacturing Locations – Ankleshwar, Bharuch, Hosur, Patancheru, and Roha
- Cumulative Global Installations Base – 200,000+ water and wastewater installations worldwide
- Core Industrial Projects Executed – 3,000+ completed projects across steel, power, and refining sectors
- Roha Chemical Facility Expansion – Advanced greenfield resin and chemical manufacturing plant
Operating manufacturing hubs across five international countries supports localized delivery for export customers. Ramping up the greenfield Roha facility expands export production capacity for pharmaceutical-grade resins and specialty chemicals.
Latest Quarterly Financial Performance of Ion Exchange (Q1 FY2027)
Ion Exchange delivered top-line turnover expansion while navigating execution cost pressures during the first quarter of FY2027.
- Consolidated Operating Revenue – Rs 700.50 crore (+20.1% YoY vs Rs 583.30 crore in Q1 FY2026)
- Consolidated Operating EBITDA – Rs 31.80 crore (-49.3% YoY vs Rs 62.70 crore in Q1 FY2026)
- Consolidated Operating EBITDA Margin – 4.54% (-622 bps YoY vs 10.75%)
- Consolidated Net Profit After Tax (PAT) – Rs 3.10 crore (-93.6% YoY vs Rs 48.40 crore in Q1 FY2026)
- Standalone Operating Revenue – Rs 635.60 crore (+22.8% YoY vs Rs 517.50 crore in Q1 FY2026)
- Standalone Net Profit After Tax (PAT) – Rs 11.40 crore (-75.7% YoY)
- Diluted Earnings Per Share (EPS) – Rs 0.35 per share
First-quarter consolidated operating revenue expanded 20.1% year-on-year to Rs 700.50 crore, supported by volume off-take in consumer products and chemicals. Consolidated Net Profit After Tax stood at Rs 3.10 crore, as cost inflation on legacy engineering projects and Roha plant commissioning expenses temporarily compressed operating margins.
Standalone & Consolidated Annual Financial Performance of Ion Exchange (FY2026)
The company achieved full-year turnover growth and operational cash conversion during full financial year FY2026.
- Full Year Consolidated Operating Revenue – Rs 2,365.80 crore (+13.2% YoY)
- Full Year Consolidated Operating EBITDA – Rs 268.40 crore (+11.5% YoY)
- Full Year Operating EBITDA Margin – 11.35%
- Full Year Consolidated Net Profit After Tax (PAT) – Rs 195.20 crore (+14.8% YoY)
- Return on Capital Employed (ROCE) Realisation – 18.50%
- Return on Equity (ROE) Realisation – 15.20%
Full-year operating turnover crossed Rs 2,360.00 crore in FY2026, as consolidated Net Profit After Tax reached Rs 195.20 crore. Delivering an operating EBITDA margin of 11.35% reflected execution across chemicals and standard treatment plants.
Balance Sheet Structure & Financial Health Ratios of Ion Exchange (Q1 FY2027)
Ion Exchange operates a low-geared balance sheet backed by cash reserves and equity retention.
- Financial Debt Status – Controlled Leverage / Net Cash Surplus
- Standalone Total Net Worth Base – ~Rs 1,180.00 crore
- Working Capital Conversion Cycle – 62 days
- Credit Rating Profile – Reaffirmed '[ICRA] AA- (Stable)'
Operating with a conservative debt profile provides balance sheet resilience to execute large EPC contracts. Credit rating agencies reaffirmed long-term ratings at '[ICRA] AA- (Stable)', confirming financial stability.
Capex Allocation & Capacity Expansion Roadmap of Ion Exchange (FY2027–FY2028)
The enterprise executes a structured capital outlay plan to scale greenfield chemical plants and expand ultra-filtration membrane lines.
- Roha Chemical Facility Expansion Capex Outlay – Rs 250.00+ crore multi-year outlay for specialty resins
- Ultra-Filtration (UF) Membrane Capacity Target – Expanding membrane manufacturing capacity at Hosur
- Standard Plant Assembly Expansion – Scaling capacity for standard water treatment systems
- Planned Annual Group Capex Guidance – Rs 120.00 to Rs 150.00 crore per annum
- Funding Strategy – 100% funded through internal operational cash accruals
Capital expenditure outlays focus on commercializing the greenfield Roha resin plant and expanding ultra-filtration membrane manufacturing lines. Internal operational cash flow generation fully funds planned facility additions without fresh long-term debt.
Strategic Outlook & Management Commentary of Ion Exchange (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on overseas backlog execution, Roha plant ramp-up, and margin normalization.
- Management projects double-digit revenue growth supported by a ~Rs 2,473.00 crore order book backlog.
- Legacy project execution cost drags in Treatment Solutions will subside over H2 FY2027.
- Roha chemical plant volume off-take will accelerate, lifting Specialty Chemicals EBIT margins back toward historical levels.
- Industrial Products segment margins expanded to 11.89% in Q1 FY2027 and will sustain strength.
- Overseas dispatches to GCC markets have resumed and will gain execution momentum.
- Capital allocation strategy will prioritize self-funded plant additions while preserving balance sheet health.
Management anticipates that liquidating international order backlogs and scaling Roha plant output will drive top-line turnover and margin recovery. Operational focus centers on executing the Hyundai contract, expanding standard plant sales, and preserving balance sheet health.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Ion Exchange Q1 FY2027 Financial Results Presentation & Stock Exchange Disclosures (August 10, 2026)
- Ion Exchange Q1 FY2027 Earnings Conference Call Transcript & Summary (August 10, 2026)
- Stock Exchange Outcomes & BSE/NSE Regulatory Filings for Ion Exchange
- Corporate Announcements & Board Meeting Results for Ion Exchange
- Ticker Finology Ion Exchange Page
Disclaimer
The information presented above on Ion Exchange has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Ion Exchange page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.